Octreotide Acetate

Octreotide Acetate is a parenteral synthetic analog of the naturally occurring hormone somatostatin. The activity of Octreotide Acetate is similar to that of somatostatin. Octreotide Acetate, however, has a longer half-life, greater selectivity for inhibiting glucagon, growth hormone, and insulin release, and a lower incidence of rebound hypersecretion following discontinuation. Based on this activity, Octreotide Acetate has been approved for the treatment of acromegaly and for use in controlling the symptoms associated with vasoactive intestinal peptide tumors (VIPomas; watery diarrhea) and metastatic carcinoid tumors (flushing and diarrhea).

Octreotide Acetate’s innovator is Novartis-Global and appears world-wide under the brand names Sandostatin and Sandostatin Lar Depot.

The pharmacologic effects of Octreotide Acetate are similar to those of somatostatin, a hypothalamic peptide. Octreotide Acetate inhibits the secretion of both pituitary and gastrointestinal. Due to the number of hormones affected by Octreotide Acetate, the actions of Octreotide Acetate are diverse.
Octreotide Acetate can inhibit the secretion of hormones involved in vasodilation. Octreotide Acetate increases splanchnic arteriolar resistance and decreases gastrointestinal blood flow, hepatic-vein wedge pressure, hepatic blood flow, portal vein pressure, and intravariceal pressure.
Because Octreotide Acetate affects many GI hormones, Octreotide Acetate is useful in controlling many types of secretory diarrhea including patients with VIPomas and AIDS-associated diarrhea. In patients with VIPomas, Octreotide Acetate reduces serum levels of VIP. As a result, stool volume decreases and hypokalemia and achlorhydria improve.
Octreotide Acetate's ability to inhibit serotonin secretion in patients with carcinoid syndrome, results in decreased flushing, diarrhea, and wheezing, as well as reduced urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA), the primary metabolite of serotonin.
Octreotide Acetate also inhibits the secretion of some anterior pituitary hormones.

Octreotide Acetate appears in the following formulation and dosage:
Sandostatin injections: 0.05mg/ml, 0.1mg/ml, 0.2mg/ml, 0.5mg/ml, 1mg/ml 
Sandostatin LAR (Long acting repeatable) - Depot powder for injection: 10 mg, 20mg and 30mg.

General data on Octreotide Acetate Active Pharmaceutical Ingredient

CAS Registry: 79517-01-4
ATC: H01CB02
Molecular Formula: C49H66N10O10S2,xC2H4O2
Molecular Weight: 1019.2 (octreotide)

TAPI's Octreotide Acetate Active Pharmaceutical Ingredient

TAPI's Octreotide Acetate Active Pharmaceutical Ingredient is produced in Assia Chemical Industries Limited - Teva Tech site in Beer Sheva, Israel.

TAPI's Octreotide Acetate has unique features that might be advantage for final dosage development. TAPI has filed several patent applications for Octreotide Acetate. Please, see table below for issued patents and pending applications.

Over the last 15 years TAPI has developed the expertise in developing and commercialization of peptide Active pharmaceutical ingredients, such as Octreotide Acetate. With numerous worldwide approvals, we are continuously driven by the goal of helping our customers achieve success-and ultimately approval for their peptide APIs. We offer grams to hundred kilograms production capabilities, comprehensive technology platform including solid phase, solution phase, and hybrid approach, combined with a well established scientific experience, enabling the implementation of efficient process aimed for high quality product. We offer Custom Synthesis and Manufacturing services on peptide Active pharmaceutical ingredients.

TAPI provide full service on Octreotide Acetate and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Octreotide Acetate.

Other peptides available on TAPI's portfolio are: Bivalirudin, Eptifibatide, Exenatide, Tariparatide Acetate, Leuprolide/ Leuprorelin Acetate and Desmopressin Acetate.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients